



Docket No. 17324 (BOT) *C OFC*

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT

In Re Application of:
DONOVAN

U.S. Patent No. 6,827,931 B1
Serial No: 09/692,811

Issued: December 7, 2004
Filed: October 20, 2000

For: METHOD FOR TREATING
ENDOCRINE DISORDERS

Certificate
JUL 13 2005
of Correction

Mail Stop Certificate of Correction
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

REQUEST FOR
CERTIFICATE OF CORRECTION
UNDER 37 C.F.R. § 1.322

Dear Sir:

Please correct the above-identified patent as shown on the accompanying Certificate of Correction Form PTO-1050.

These corrections are requested for the following reasons:

IN THE SPECIFICATION:

Col. 1, line 10, after "gland", insert .. gland ..

Col. 1, line 12, after "anterior lobe", replace "adenohypophysis" with ..
adenohypophysis ..

Col. 1, line 24, after "adrenocorticotropin", replace "(corticotropin" with ..
(corticotrophin) ..

Col. 1, line 35, after "and the", replace "parahippocmpal" with ..
parahippocampal ..

Col. 1, line 41, after "optic chiasma", insert .. , ..

Col. 1, line 42, after "infundibulum", insert .. , ..

Col. 1, line 49, before ", dorsomedial", replace "ventmmedial" with ..
ventromedial ..

Col. 1, line 57, after "involved", replace "In" with .. in ..

Col. 2, line 15, after "and the", replace "adenohypophysis" with ..
adenohypophysis ..

Col. 2, line 29, after "levels", replace "Increased" with .. increased ..

Col. 2, line 41, after "Potassium", replace "Depoladzation" with ..

Depolarization ..

Col. 2, line 43, after "(8):", replace "268" with .. 2686 ..

Col. 2, line 49, after "effect", insert .. can ..

Col. 2, line 51, after "Compensatory", replace "Hypertophy" with ..

Hypertrophy ..

Col. 2, line 52, after "Hypothalamus," replace "Eperimentia" with ..

Experientia ..

Col. 3, line 57, after "radiation", replace "Injury" with .. injury ..

Col. 4, line 25, after "can also", replace "based be" with .. be based ..

Col. 6, line 61, after "B and C1", replace "is" with .. are ..

Col. 7, line 3, after "relevant", replace "heurotoxin" with .. neurotoxin ..

Col. 7, line 5, after "toxin", replace "Is" with .. is ..

Col. 7, line 12, after "potassium", replace "ation" with .. cation ..

Col. 7, line 25, after "681:", replace "1897" with .. 1987 ..

Col. 8, line 14, after "and Use of", replace "Properties" with .. Properties ..

Col. 8, line 39, after "such", replace "a" with .. as ..

Col. 8, line 45, before "peptidases", replace "Intracellular" with ..

intracellular ..

Col. 8, line 49, before "known", replace "Is" with .. is ..

Col. 8, line 59, after "can", insert .. be .. after "can"

Col. 9, line 10, before "stored", replace "Is" with .. is ..

Col. 9, line 34, after "intramuscular", replace "injectiori" with .. injection ..

Col. 10, line 1, before "significant", replace "showed" with .. shown ..

Col. 10, line 9, after "although", replace "R" with .. it ..

Col. 10, line 15, after "S111", replace "S11150" with .. S115 ..

Col. 10, line 16, after "the", replace "Laiyngoscope" with .. Laryngoscope ..

Col. 10, line 36, after "the", replace "later" with .. latter ..

Col. 11, line 12, before "Schmiedeberg's", replace "Nauny" with .. Naunyn ..

Col. 11, line 13, before "Schmiedeberg's", replace "Nauny" with .. Naunyn ..

Col. 11, line 63, before "system", replace "sympathetic.nervous" with ..

sympathetic nervous ..

Col. 12, line 8, after "such as", replace "such as, adrenal" with .. such as
adrenal ..

Col. 12, line 9, after "cells", insert .. , ..

Col. 12, line 30, after "membrane", replace "Ion" with .. ion ..

Col. 12, line 42, after "Pontomesencephalic", replace "Choinergic" with ..

Cholinergic ..

Col. 12, line 63, before "cholinergic", replace "Ch5 Ch6" with .. Ch5-Ch6 ..

Col. 12, line 65, before "in the midbrain", replace "structure" with --
structures --

Col. 13, line 5, after "CRC Press", replace "(19950" with -- (1995) --

Col. 13, line 8, before "Central", replace "L" with -- I. --

Col. 13, line 12, after "Press", replace "(1 i995)" with -- 1995 --

Col. 13, line 13, replace line with -- 136-139 --

Col. 13, line 15, after "cholinergic", replace "Innervation" with -- innervation --

Col. 13, line 17, after "page", replace "136-136" with -- 136 --

Col. 13, line 34, after "there", replace "Is" with -- is --

Col. 13, line 58, after "and", replace "In" with -- in --

Col. 13, line 64, before "neuroendocrine", replace "an" with -- a --

Col. 14, line 14, after "proteins", insert -- . -- after "proteins"

Col. 14, line 25, after "Clostridium", replace "beratt" with -- beratti --

Col. 14, line 67, after "toxin)", replace "toxin)with" with -- toxin) with"

Col. 15, line 8, before "invention", replace "present. invention" with -- present
invention --

Col. 15, line 27, after "native", insert -- neurotoxin --

Col. 15, line 29, after "derivative or", replace "or" with -- thereof --

Col. 16, line 7, before "lasting", replace "lost" with -- long --

Col. 16, line 34, after "prevention", insert -- of --

Col. 16, line 37, after "theory", insert -- , --

Col. 17, line 2, after "hypothalamus", replace "and or" with -- and / or --

Col. 17, line 24, before "Implant", replace "Intersitial" with -- Interstitial --

Col. 17, line 39, after "polyanhydride", replace "waters" with -- wafers --

Col. 17, line 59, after "Recurrent", replace "Gilomas" with -- Gliomas --

Col. 17, line 59, after "Lancet 345:", replace "10081012" with -- 1008-1012 --

Col. 17, line 64, after "then", insert -- be -- after "then"

Col. 18, line 17, after "toxins", insert -- , -- after "toxins"

Col. 18, line 21, after "brain", replace "barrer" with -- barrier --

Col. 18, line 23, after "for use", replace "In" with -- in --

Col. 18, line 24, after "09/587250", insert -- , -- after "09587250"

Col. 18, line 37, after "alia", replace "hypergonadotrophism" with --

hypergonadotrophism --

Col. 19, line 16, after "tissue involvement", insert -- the tissue -- after "or"

Col. 19, line 17, after "chosen", insert -- , -- after "chosen"

Col. 19, line 34, after "delivered", insert -- to --

Col. 19, line 40, after "target", insert -- . -- after "target"

Col. 20, line 3, before "a method", replace "Signiflcantly" with -- Significantly

Col. 20, line 9, after "function", replace "Is" with -- is --

Col. 20, line 10, before "using", replace "assesses" with -- assessed --

Col. 20, line 52, before "to the", replace "approached" with -- approach --

Col. 21, line 6, before "(Axon", replace "Micmpositioner" with ..
Micropositioner ..

Col. 21, line 8, after "CRW", replace "sterotaxis" with .. stereotaxis ..
Col. 21, line 17, after "for a", replace "continuos" with .. continuous ..
Col. 21, line 26, before "procedures", replace "Sterootactic" with .. Stereotactic ..

Col. 21, line 30, after "endocrine", insert .. disorder ..
Col. 21, line 42, before "electrode", replace "a" with .. an ..
Col. 21, line 58, after "can be", replace "uses" with .. used ..
Col. 21, line 64, after "release of", insert .. a ..
Col. 22, line 63, after "polymeric", replace "implants" with .. implant ..
Col. 22, line 65, after "such as a", delete "of"
Col. 23, line 6, after "each side", replace "o" with .. of ..
Col. 23, line 8, after "subsequent", replace "24 months" with .. 2-4 month ..
Col. 23, line 40, after "polymeric," replace "implants" with .. implant ..
Col. 23, line 42, after "as an", replace "alternitive" with .. alternative ..
Col. 24, line 1, after "polymeric", replace "implants" with .. implant ..
Col. 24, line 4, after "such as a", delete "of"
Col. 24, line 9, before "point", insert .. the .. before "point"
Col. 24, line 11, after "side", replace "o" with .. of ..
Col. 24, line 13, after "subsequent", replace "24" with .. 2-4 ..
Col. 24, line 28, after "Inhibition of", replace "Gametogenesis" with ..

Gametogenesis ..

Col. 24, line 35, before "injected", delete "is"
Col. 24, line 42, after "such as a", delete "of"
Col. 24, line 48, before "point", insert .. the .. before "point"
Col. 24, line 49, after "each side", replace "o" with .. of ..
Col. 24, line 53, after "method for use", replace "In" with .. in ..
Col. 24, line 65, before "thereby inducing", delete "thereby,"
Col. 25, line 18, after "herein", delete "for"
Col. 25, line 26, after "implantation", delete "use"
Col. 25, line 30, after "secretion", replace "suppmssant" with .. suppressant ..
Col. 26, line 2, after "neurotoxin", replace "proved" with .. provide ..
Col. 26, line 27, after "selected", replace "form" with .. from ..
Col. 26, line 54, after "selected", replace "form" with .. from ..
Col. 27, line 3, after "selected", replace "form" with .. from ..

The Commissioner is hereby authorized to charge any additional and necessary fees as required for the filing, processing of any of the enclosed papers, or to credit any overpayment, to Deposit Account number 01-0885.

Please send the Certificate to:

Allergan, Inc.
STEPHEN DONOVAN (T2-7H)
Intellectual Property Dept.
2525 Dupont Drive
Irvine, CA 92612

July 5, 2005

Respectfully Submitted,



Stephen Donovan
Registration No. 33,433
Telephone: 714/246-4026
Telecopier: 714/246-4249

Allergan, Inc.
2525 Dupont Drive
Irvine, CA 92612

CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST-CLASS MAIL WITH SUFFICIENT POSTAGE IN AN ENVELOPE ADDRESSED TO THE: MAIL STOP CERTIFICATE OF CORRECTION, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 ON JULY 5, 2005.

Printed Name of Person Making Deposit: Adriane Giberson;

Signature of Person Making Deposit: Adriane Giberson Date: JULY 5, 2005

**UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION**

PATENT NO. : 6,827,931 B1

APPLICATION NO. :

ISSUE DATE : December 7, 2004

INVENTOR(S) : DONOVAN

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

IN THE SPECIFICATION:

Col. 1, line 10, after "gland", insert -- gland --
 Col. 1, line 12, after "anterior lobe", replace "adenohypophysis" with --adenohypophysis --
 Col. 1, line 24, after "adrenocorticotropin", replace "(corticotropin" with -- (corticotrophin) --
 Col. 1, line 35, after "and the", replace "parahippocmpal" with -- parahippocampal --
 Col. 1, line 41, after "optic chiasma", insert -- , --
 Col. 1, line 42, after "infundibulum", insert -- , --
 Col. 1, line 49, before ", dorsomedial", replace "ventmmedial" with -- ventromedial --
 Col. 1, line 57, after "involved", replace "In" with -- in --
 Col. 2, line 15, after "and the", replace "adenohypophysis" with -- adenohypophysis --
 Col. 2, line 29, after "levels", replace "Increased" with -- increased --
 Col. 2, line 41, after "Potassium", replace "Depoladzation" with -- Depolarization --
 Col. 2, line 43, after "(8):", replace "268" with -- 2686 --
 Col. 2, line 49, after "effect", insert -- can --
 Col. 2, line 51, after "Compensatory", replace "Hypertophy" with -- Hypertrophy --
 Col. 2, line 52, after "Hypothalamus," replace "Eperientia" with --Experientia--
 Col. 3, line 57, after "radiation", replace "Injury" with -- injury --
 Col. 4, line 25, after "can also", replace "based be" with -- be based --
 Col. 6, line 61, after "B and C₁", replace "is" with -- are --
 Col. 7, line 3, after "relevant", replace "heurotoxin" with -- neurotoxin --
 Col. 7, line 5, after "toxin", replace "Is" with -- is --
 Col. 7, line 12, after "potassium", replace "ation" with -- cation --
 Col. 7, line 25, after "681:", replace "1897" with -- 1987 --
 Col. 8, line 14, after "and Use of", replace "Properies" with -- Properties --
 Col. 8, line 39, after "such", replace "a" with -- as --
 Col. 8, line 45, before "peptidases", replace "Intracellular" with -- intracellular --
 Col. 8, line 49, before "known", replace "Is" with -- is --
 Col. 8, line 59, after "can", insert -- be -- after "can"
 Col. 9, line 10, before "stored", replace "Is" with -- is --

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Att. Stephen Donovan, Allergan, Inc., Intellectual Property Dept.
 2525 Dupont Dr., T2-7H, Irvine, CA 92612

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION**

Col. 9, line 34, after "intramuscular", replace "injectioni" with -- injection --
 Col. 10, line 1, before "significant", replace "showed" with -- shown --
 Col. 10, line 9, after "although", replace "R" with -- it --
 Col. 10, line 15, after "S111-", replace "S11150" with -- S115 --
 Col. 10, line 16, after "the", replace "Laiyngoscope" with -- Laryngoscope --
 Col. 10, line 36, after "the", replace "later" with -- latter --
 Col. 11, line 12, before "-Schmiedeberg's", replace "Nauny" with -- Naunyn --
 Col. 11, line 13, before "-Schmiedeberg's", replace "Nauny" with -- Naunyn --
 Col. 11, line 63, before "system", replace "sympathetic.nervous" with -- sympathetic nervous --
 Col. 12, line 8, after "such as", replace "such as, adrenal" with -- such as adrenal --
 Col. 12, line 9, after "cells", insert -- , --
 Col. 12, line 30, after "membrane", replace "Ion" with -- ion --
 Col. 12, line 42, after "Pontomesencephalic", replace "Choinergic" with -- Cholinergic --
 Col. 12, line 63, before "cholinergic", replace "Ch5 Ch6" with -- Ch5-Ch6 --
 Col. 12, line 65, before "in the midbrain", replace "structure" with -- structures --
 Col. 13, line 5, after "CRC Press", replace "(19950" with -- (1995) --
 Col. 13, line 8, before "Central", replace "L" with -- I. --
 Col. 13, line 12, after "Press", replace "(1 i995)" with -- 1995 --
 Col. 13, line 13, replace line with -- 136-139 --
 Col. 13, line 15, after "cholinergic", replace "Innervation" with -- innervation --
 Col. 13, line 17, after "page", replace "136-136" with -- 136 --
 Col. 13, line 34, after "there", replace "Is" with -- is --
 Col. 13, line 58, after "and", replace "In" with -- in --
 Col. 13, line 64, before "neuroendocrine", replace "an" with -- a --
 Col. 14, line 14, after "proteins", insert -- . -- after "proteins"
 Col. 14, line 25, after "Clostridium", replace "beratt" with -- beratti --
 Col. 14, line 67, after "toxin)", replace "toxin)with" with -- toxin) with"
 Col. 15, line 8, before "invention", replace "present. invention" with -- present invention --
 Col. 15, line 27, after "native", insert - neurotoxin --
 Col. 15, line 29, after "derivative or", replace "or" with -- thereof --
 Col. 16, line 7, before "lasting", replace "lost" with -- long --
 Col. 16, line 34, after "prevention", insert -- of --
 Col. 16, line 37, after "theory", insert -- , --
 Col. 17, line 2, after "hypothalamus", replace "and or" with -- and / or --
 Col. 17, line 24, before "Implant", replace "Intersitial" with -- Interstitial --
 Col. 17, line 39, after "polyanhydride", replace "waters" with -- wafers --
 Col. 17, line 59, after "Recurrent", replace "Gliomas" with -- Gliomas --
 Col. 17, line 59, after "Lancet 345:", replace "10081012" with -- 1008 -1012 --
 Col. 17, line 64, after "then", insert -- be -- after "then"
 Col. 18, line 17, after "toxins", insert -- , -- after "toxins"
 Col. 18, line 21, after "brain", replace "barrer" with -- barrier --
 Col. 18, line 23, after "for use", replace "In" with -- in --
 Col. 18, line 24, after "09/587250", insert -- , -- after "09587250"
 Col. 18, line 37, after "alia", replace "hypergonadotrophism" with -- hypergonadotrophism --

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Att. Stephen Donovan, Allergan, Inc., Intellectual Property Dept.
 2525 Dupont Dr., T2-7H, Irvine, CA 92612

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION**

Col. 19, line 16, after "tissue involvement", insert -- the tissue -- after "or"
 Col. 19, line 17, after "chosen", insert -- , -- after "chosen"
 Col. 19, line 34, after "delivered", insert -- to --
 Col. 19, line 40, after "target", insert -- . -- after "target"
 Col. 20, line 3, before "a method", replace "Significantly" with -- Significantly --
 Col. 20, line 9, after "function", replace "Is" with -- is --
 Col. 20, line 10, before "using", replace "assesses" with -- assessed --
 Col. 20, line 52, before "to the", replace "approached" with -- approach --
 Col. 21, line 6, before "(Axon", replace "Micmpositioner" with -- Micropositioner --
 Col. 21, line 8, after "CRW", replace "sterotaxis" with -- stereotaxis --
 Col. 21, line 17, after "for a", replace "continuos" with -- continuous --
 Col. 21, line 26, before "procedures", replace "Sterootactic" with -- Stereotactic --
 Col. 21, line 30, after "endocrine", insert -- disorder --
 Col. 21, line 42, before "electrode", replace "a" with -- an --
 Col. 21, line 58, after "can be", replace "uses" with -- used --
 Col. 21, line 64, after "release of", insert -- a --
 Col. 22, line 63, after "polymeric", replace "implants" with -- implant --
 Col. 22, line 65, after "such as a", delete "of"
 Col. 23, line 6, after "each side", replace "o" with -- of --
 Col. 23, line 8, after "subsequent", replace "24 months" with -- 2-4 month --
 Col. 23, line 40, after "polymeric," replace "implants" with -- implant --
 Col. 23, line 42, after "as an", replace "alternitive" with -- alternative --
 Col. 24, line 1, after "polymeric", replace "implants" with -- implant --
 Col. 24, line 4, after "such as a", delete "of"
 Col. 24, line 9, before "point", insert -- the -- before "point"
 Col. 24, line 11, after "side", replace "o" with -- of --
 Col. 24, line 13, after "subsequent", replace "24" with -- 2-4 --
 Col. 24, line 28, after "Inhibition of", replace "Gametogenesis" with -- Gametogenesis --
 Col. 24, line 35, before "injected", delete "is"
 Col. 24, line 42, after "such as a", delete "of"
 Col. 24, line 48, before "point", insert -- the -- before "point"
 Col. 24, line 49, after "each side", replace "o" with -- of --
 Col. 24, line 53, after "method for use", replace "In" with -- in --
 Col. 24, line 65, before "thereby inducing", delete "thereby,"
 Col. 25, line 18, after "herein", delete "for"
 Col. 25, line 26, after "implantation", delete "use"
 Col. 25, line 30, after "secretion", replace "suppmssant" with -- suppressant --
 Col. 26, line 2, after "neurotoxin", replace "proved" with -- provide --
 Col. 26, line 27, after "selected", replace "form" with -- from --
 Col. 26, line 54, after "selected", replace "form" with -- from --
 Col. 27, line 3, after "selected", replace "form" with -- from --

MAILING ADDRESS OF SENDER (Please do not use customer number below):

Att. Stephen Donovan, Allergan, Inc., Intellectual Property Dept.
 2525 Dupont Dr., T2-7H, Irvine, CA 92612

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.